Blue Latitude Opens New Office in NY
News Jul 14, 2016
Blue Latitude Health has announced the opening of new office in New York City. We will initially offer strategic consulting services from the new location, with the intention to roll out our full suite of services for US clients in the near future. Headquartered in London, UK, we have worked with US and global clients for 13 years, providing strategic expertise for healthcare clients to better engage with their customers.
Building on this success, we are rapidly expanding with the aim of building new relationships with, and providing our services to, a wider range of companies in the US, the world’s single largest healthcare market and the global base of many of the world’s healthcare companies. We work with brand and franchise leads to help them optimally position their launch products, and reposition in-market products that are experiencing market changes, with the aim of maximising the products’ commercial potential.
Our unique combination of expertise, strategy and in-depth knowledge of the sector has enabled us to build a solid client base that includes some of the most influential healthcare brands in the world, such as Janssen, Bristol-Myers Squibb, Pfizer and AbbVie. Over the last year, Blue Latitude Health worked as the sole agency on several projects for global, as well as regional, brand and medical teams, delivering innovative capability building projects; such as Lilly’s Medical Information Cascade, which culminated in a PMEA Innovation award at the end of 2015, working with Lilly’s Global Medical Education team.
Martin Brass, Co-Founder and Managing Director at Blue Latitude Health, said: We are very excited to be expanding and opening an office in New York City, where we will be able to service our existing clients better and connect with a wider group of healthcare, life sciences and pharmaceutical companies in the US. Our model of ‘strategy through creativity’ is gaining measurable traction with clients making us very confident that our expansion and growth will be supported by quality delivery that continues to exceed our clients’ expectations.
Fred Bassett, Co-Founder and Head of Strategy at Blue Latitude Health, added: The opening of our US office marks the achievement of another exciting milestone in BLH’s growth. We still feel we're just scratching the surface of what we're capable of in terms of the value we can bring to our clients. We believe there is a major opportunity for our innovative approach, and with this step into the US, we are demonstrating our commitment to making our business truly global.
The new US office will open with two consultants; James Atherton (Managing Consultant, US Vice President) and David Cooney (Consultant), bringing with them culture, frameworks, processes and knowledge, with the aim to grow rapidly, employing further consultants and support staff in the coming year.
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019
16th International Conference on Structural Biology
Mar 11 - Mar 12, 2019